Amgen Inc.
Amgen Announces Retirement of Chief Technology Officer David M. Reese
Summary
Amgen Inc. announced on April 22, 2026, that David M. Reese, Executive Vice President and Chief Technology Officer, will retire effective June 30, 2026. His responsibilities will be redistributed to James E. Bradner, Murdo Gordon, and Peter H. Griffith. Dr. Reese, who joined Amgen in 2005, led approvals of numerous innovative medicines and advanced the company's adoption of technology and artificial intelligence.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement